       Document 0025
 DOCN  M9610025
 TI    In vitro antibiotic susceptibility testing of clinical isolates of
       Mycoplasma penetrans from patients with AIDS.
 DT    9601
 AU    Hayes MM; Foo HH; Timenetsky J; Lo SC; Department of Infectious and
       Parasitic Disease Pathology, Armed; Forces Institute of Pathology,
       Washington, D.C. 20306-6000, USA.
 SO    Antimicrob Agents Chemother. 1995 Jun;39(6):1386-7. Unique Identifier :
       AIDSLINE MED/96012208
 AB    In vitro susceptibilities of Mycoplasma penetrans were determined. MICs
       and MBCs were determined. The MICs at which 50% of the isolates are
       inhibited (micrograms per milliliter) for broth dilution testing were as
       follows: azithromycin, 0.039; chloramphenicol, 0.625; ciprofloxacin,
       0.156; clindamycin, 0.078; doxycycline, 0.312; erythromycin, 0.312;
       gentamicin. > 10; levofloxacin, 0.078; lincomycin, 0.625; streptomycin,
       > 10; and tetracycline, 1.25. Bactericidal activity was significant only
       for ciprofloxacin (MBC at which 50% of the isolates are killed, 0.312
       microgram/ml) and levofloxacin (MBC at which 50% of the isolates are
       killed, 0.312 microgram/ml).
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS/DRUG THERAPY
       Antibiotics/*PHARMACOLOGY  AIDS-Related Opportunistic
       Infections/COMPLICATIONS/DRUG THERAPY  Human  Microbial Sensitivity
       Tests  Mycoplasma penetrans/*DRUG EFFECTS  Mycoplasma
       Infections/COMPLICATIONS/DRUG THERAPY  Support, U.S. Gov't, P.H.S.
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

